血小板膜糖蛋白受体GPIIb/IIIa在血栓性疾病的发生发展及药物治疗中起重要作用，但目前对其遗传变异及其在药物反应差异中的作用尚存争议。本项目以前期工作已获得的GPIIb/IIIa基因单核苷酸多态性（SNP）和基因型/药效相关性研究结果为基础，首先在群体水平分析健康人和冠心病患者GPIIb、GPIIIa SNPs分布特征；然后构建稳定表达GPIIb、GIIIa野生型和突变等位基因的转基因细胞系，在细胞水平研究各突变等位基因对受体的表达、亲和力和效能等生物学功能的影响；最后在此基础上选取不同基因型的急性冠脉综合征和行PCI术患者，分别采用氯吡格雷和阿昔单抗进行常规临床抗血小板治疗，观察临床疗效、不良反应等，验证基因型与药效关系。本课题旨在从群体、细胞到分子水平阐明GPIIb、GPIIIa多态性在药物反应个体差异及疾病发生中的作用。

Large interindividual pharmacodynamics (PD) variability for antithrombotic treatment is commonly observed, and the role of genetic polymorphisms of the GP IIb/IIIa receptor has been investigated. But the results of these studies are inconsistent. The present program aimed to examine the effects of single-nucleotide polymorphisms (SNPs) in GPIIb and GPIIIa gene base on the results of our previous work in clinical trails and DNA sequencing. Second, build a stable transgenic cell line expressing GPIIb and GPIIIa wild-type and mutant alleles, investigate the effect of each mutant allele on receptor expression, affinity and efficacy. Third, we intended to assess the impact of these SNPs on clopidogrel and abciximab pharmacodynamics in patient with acute coronary syndrome. The ultimate goal is to investigate the SNPs function, and to clarify the role of these genotypes in interindividual PD variability for antithrombotic treatment.